News and Events
Study available at U-M evaluates reparixin in combination with paclitaxel for metastatic triple-negative breast cancer
Triple-negative is the most aggressive kind of breast cancer. Triple negative tumors are negative for estrogen receptor, progesterone receptor and the HER2 protein. Because treatments that target these proteins would not work in triple negative breast cancer, the main treatment for it is chemotherapy.
In a randomized clinical trial conducted by researchers at University of Southampton, biliary cancer patients treated with capecitabine as adjuvant therapy lived, on average, more than a year longer than those who were only observed, according to a post in HemOnc Today.
The Daily Mail reports that a new study, released in advance of the upcoming American Society of Clinical Oncology annual meeting, links the regular consumption of tree nuts such as almonds, cashews and Brazil nuts, to better outcomes for colon cancer patients.
In work that could improve understanding of how cancer spreads, a team of engineers and medical researchers at the University of Michigan developed a new kind of microfluidic chip that can capture rare, aggressive cancer cells, grow them on the chip and release single cells on demand.
Researchers at Michigan Medicine have found a protein that stops cancer’s ability to prevent the immune system from destroying cancer cells. The protein is called free C3d, and it has the potential to be developed into a cancer vaccine and a cancer treatment.